# US 2025/0082600 A1 · Treating haematological malignancies by means of satraplatin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082600 A1
- Document ID: US20250082600A1
- Status: Published application
- Kind: A1
- Application number: 18/726,703
- Filed: 2022-12-20
- Published: 2025-03-13
- Earliest claimed: 2022-01-07
- Applicants: Pharma& Schweiz GmbH
- Inventors: Felix DAHM; Thilo Joachim ZANDER; Christoph Robert RENNER; Gabriel Benjamin MARKSON
- Web page: https://patentgrep.com/patent/US20250082600A1

## CPC

- A61K 31/282: Platinum compounds
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to medical uses and methods of treatment employing satraplatin. These medical uses are beneficial in treatment of cancers, particularly haematological malignancies. The invention also relates to methods of patient stratification and methods for the selection of treatment regimens, as well as to diagnostic methods and to biomarker panels.

## Claims

### Claim 1

Satraplatin for use in the treatment of a haematological malignancy in a patient identified as likely to benefit from such treatment by analysis of a gene selected from the group consisting of: a gene located in the 9p21 locus (such as MTAP, CDKN2B, CDKN2A, or DMRTA1); BCL2; TULP3; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; AP4E1; PAN3; AC073343.11.1; PHF2; KLHDC1; and WRN.

### Claim 2 (depends on 1)

Satraplatin for use according to claim 1, wherein the haematological malignancy is a lymphoma or myeloma.

### Claim 3 (depends on 2)

Satraplatin for use according to claim 2, wherein the lymphoma or myeloma is selected from the group consisting of: diffuse large B cell lymphoma (DLBCL); Burkitt lymphoma; mantle cell lymphoma; peripheral T cell lymphoma (PTCL); anaplastic large cell lymphoma (ALCL); primary DLBCL of the central nervous system (CNS); secondary CNS lymphoma (SCNSL); cutaneous T cell lymphoma; Sézary syndrome; and multiple myeloma.

### Claim 4 (depends on 1, 2, 3)

Satraplatin for use according to any of claims 1 to 3, wherein the gene is one located in the 9p21 locus, and the analysis identifies reduced copy numbers of the gene.

### Claim 5 (depends on 4)

Satraplatin for use according to claim 4, wherein the gene is selected from the group consisting of: MTAP; CDKN2B; CDKN2A; and DMRTA1, and the analysis identifies a deficiency of the gene.

### Claim 6 (depends on 4, 5)

Satraplatin for use according to claim 4 or claim 5, wherein the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; CTCL; multiple myeloma; ALCL ALK+; and mantle cell lymphoma.

### Claim 7 (depends on 1, 2, 3)

Satraplatin for use according to any of claims 1 to 3, wherein the gene is selected from the group consisting of: BCL2; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; and AP4E1, and the analysis identifies mutation of the gene.

### Claim 8 (depends on 8)

Satraplatin for use according to claim 8, wherein the mutation is selected from those set out in Table 1 and Table 2.

### Claim 9 (depends on 7, 8)

Satraplatin for use according to claim 7 or claim 8, wherein the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; and ALCL ALK+.

### Claim 10 (depends on 1, 2, 3)

Satraplatin for use according to any of claims 1 to 3, wherein the gene is selected from the group consisting of: TULP3; PAN3; AC073343.11.1; PHF2; KLHDC1; BRCA2; and WRN, and the analysis identifies elevated expression of the gene.

### Claim 11

Satraplatin for use in the treatment of a haematological malignancy with a loss of the 9p21 locus.

### Claim 12

Satraplatin for use in the treatment of a haematological malignancy with a deficiency of a gene selected from the group consisting of: MTAP; CDKN2B; CDKN2A; and DMRTA1.

### Claim 13 (depends on 12)

Satraplatin for use according to claim 12, wherein the deficiency is reduced copy number of the gene selected from the group consisting of: MTAP; CDKN2B; CDKN2A; and DMRTA1.

### Claim 14 (depends on 11, 12, 13)

Satraplatin for use according to any of claims 11 to 13, wherein the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; CTCL; multiple myeloma; ALCL ALK+; and mantle cell lymphoma.

### Claim 15

Satraplatin for use in the treatment of a haematological malignancy with mutation of a gene selected from the group consisting of: BCL2; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; and AP4E1.

### Claim 16 (depends on 15)

Satraplatin for use according to claim 15, wherein the mutation is selected from the group set out in Table 1 and Table 2.

### Claim 17 (depends on 15, 16)

Satraplatin for use according to claim 15 or claim 16, wherein the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; and ALCL ALK+.

### Claim 18

Satraplatin for use in the treatment of a haematological malignancy with elevated expression of TULP3; PAN3; AC073343.11.1; PHF2; KLHDC1; BRCA2; or WRN.

### Claim 19

A method of determining the likelihood of a haematological malignancy responding favourably to satraplatin treatment, the method comprising:
analysing a cell of the haematological malignancy for a change in a gene selected from the group consisting of: a gene located in the 9p21 locus (such as MTAP, CDKN2B, CDKN2A, or DMRTA1); BCL2; TULP3; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; AP4E1; PAN3; AC073343.11.1; PHF2; KLHDC1; and WRN; wherein
identification of a change in the gene analysed indicates that the haematological malignancy is likely to respond favourably to satraplatin treatment.

### Claim 20

A signature panel characteristic of sensitivity of a haematological malignancy to treatment with satraplatin, the panel comprising:
loss of copy number of at least one gene selected from the group consisting of: MTAP; CDKN2B; CDKN2A; and DMRTA1; and/or
a mutation of at least one gene selected from the group consisting of: BCL2; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; and AP4E1; and/or
elevated expression of at least one gene selected from the group consisting of: TULP3; PAN3; AC073343.11.1; PHF2; KLHDC1; BRCA2; and WRN.

### Claim 21 (depends on 20)

A signature panel according to claim 20, wherein:
the gene with reduced copy number is selected from the group consisting of: MTAP; CDKN2B; CDKN2A; and DMRTA1, and
the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; CTCL; multiple myeloma; ALCL ALK+; and mantle cell lymphoma.

### Claim 22 (depends on 20)

A signature panel according to claim 20, wherein:
the gene with a mutation is selected from the group consisting of: BCL2; AOC1; BOC; DDX3X; CRYBG3; SLFN5; ETNK2; BRCA2; USP22; KIAA1683; and AP4E1, and
the mutation is selected from the group set out in Table 1 and Table 2, and
the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; and ALCL ALK+.

### Claim 23 (depends on 20)

A signature panel according to claim 20, wherein the gene is selected from the group consisting of: TULP3; PAN3; AC073343.11.1; PHF2; KLHDC1; BRCA2; and WRN, and the analysis identifies elevated expression of the gene.

### Claim 24

A signature biomarker panel characteristic of sensitivity of a haematological malignancy to treatment with satraplatin, the panel comprising at least one gene mutation selected from the group set out in Table 1 and Table 2, wherein the haematological malignancy is selected from the group consisting of: Burkitt lymphoma; DLBCL; and ALCL ALK+.

### Claim 25

Satraplatin for use as a second line therapy in the treatment of cancer non-responsive to immune checkpoint therapy.
